• In the second quarter of 2026, Celcuity Inc. reported a net loss of US$78.86 million, or US$1.44 per share, with first-half net loss widening to US$131.71 million and loss per share reaching US$2.41, both higher than the same periods a year earlier.
• The sharp increase in reported losses underscores how Celcuity’s spending profile is evolving as it advances gedatolisib through clinical development and prepares for potential commercialization.
• With these larger recent losses in mind, we’ll now examine how Celcuity’s earnings trajectory affects the earlier investment narrative around gedatolisib.

Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Celcuity Investment Narrative Recap

To own Celcuity today, you need to believe gedatolisib can justify the company’s growing investment as it moves from late stage development into commercialization. The latest quarter’s larger net loss does not change the core near term catalyst, which is the launch and early uptake of REVTORPYK in HR+/HER2– breast cancer. However, it does sharpen the most immediate risk: whether future REVTORPYK revenue can keep pace with a higher, more persistent cash burn.

Among recent announcements, the July 2026 FDA approval of REVTORPYK is the clear counterweight to these widening losses. It gives Celcuity its first commercial product in HR+/HER2–, PIK3CA wild type advanced breast cancer after endocrine therapy. How quickly oncologists prescribe REVTORPYK, and how payers respond, will be central to whether the current loss profile begins to improve or remains a pressure point as additional trials and indications progress.

Yet against this approval milestone, the step up in quarterly losses is a reminder that investors should also be aware of how Celcuity’s heavier financing commitments could...

Celcuity's narrative projects $817.9 million revenue and $267.5 million earnings by 2029. This implies an earnings increase of about $460 million from -$192.9 million today.

Uncover how Celcuity's forecasts yield a $161.09 fair value, a 77% upside to its current price.

Exploring Other Perspectives

Some of the more cautious analysts were already assuming only about US$535,000,000 of revenue and US$22,000,000 of earnings by 2029, so this larger loss may either reinforce their concern about ongoing cash burn or prompt a rethink if REVTORPYK’s launch and future VIKTORIA trial readouts start to look stronger than those earlier expectations.

Explore 4 other fair value estimates on Celcuity - why the stock might be worth over 5x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Celcuity research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Celcuity research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Celcuity's overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.